What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Dr. John Cush RheumNow
3 years 5 months ago
Multinational recs. on Rx of JIA assoc. Uveitis:
- Topical steroids are 1st line Rx
- Systemic Rx if above fails or w/ poor prognosis or persistence
- Options MTX, MMF then Humira EOW, then weekly ADA
- Consider non-ETN TNFi's, then TCZ, ABA, JAKi or RTX https://t.co/ZfVeWf5sVg https://t.co/yu3to0LdEd
Dr. John Cush RheumNow
3 years 5 months ago
Podcast on Podcasting
A tutorial on podcasting - what works and what does not.
https://t.co/QINseXd6Z2 https://t.co/OFuVacgcfq
Dr. John Cush RheumNow
3 years 5 months ago
Environmental articulate matter (PM2.5) levels can increase the odds of a systemic autoimmune rheumatic disease onset (OR 1.12; 1.08–1.15), , w/ no effect of ozone. Results not changed by controlling for smoking. https://t.co/7BGBh9h0lf https://t.co/LcUo4Lxzgx
Dr. John Cush RheumNow
3 years 5 months ago
Axial PsA: Is it for Real?
Dr. Janet Pope ( @Janetbirdope) presenting from EULAR 2022.
https://t.co/0smaACel5k https://t.co/UJ3hi3rJlY
Dr. John Cush RheumNow
3 years 5 months ago
Lupus Research Alliance’s has awarded the Lupus Insight Prize to Akiko Iwasaki, PhD (professor at Yale School of Medicine) for her research on the pathogenic role of retroviruses in lupus published in Journal of Experimental Medicine https://t.co/xmQjFLk63K https://t.co/68Ezlfk00j
Dr. John Cush RheumNow
3 years 5 months ago
Lower Fx risk in PsA Rx w/ biologics? Review of 100 RCTs, 51,413 Pso & PsA pts; pts on bDMARDs had signif lower risk of major OP Fx (OR 0.34), hip Fx (OR 0.22) & OP non-vertebral Fx (OR 0.26). Fx risk not changed in RA, axSpA, SLE, IBD pts on biologics https://t.co/Acv1q1K5A9 https://t.co/dAaq2EsTDK
Dr. John Cush RheumNow
3 years 5 months ago
RWE & Registries in Psoriatic Arthritis
Dr. Alexis Ogdie presents RWE & Registries in Psoriatic Arthritis at the 2022 RheumNow Live meeting.
https://t.co/zYcDrhgbNr https://t.co/s4Hv3ub9Av
A cohort study of rheumatoid arthritis (RA) patients evaluated immunogenicity of COVID vaccination with and without holding methotrexate (MTX) for and 2-weeks and showed better immunogenicity, but more RA flares with the second MTX withdrawal.
Dr. John Cush RheumNow
3 years 5 months ago
Metanalysis of 7 studies shows that oral anticoagulants need not be discontinued for joint injections or aspiration. Only pts w/ hemorrhage after 5427 procedures, over 32-yrs. INR values of 3 bleeding cases was 1.9, 2.3, and 3.4. https://t.co/l130TsksVi https://t.co/OD7SSBuAS0
A tutorial on podcasting - what works and what does not, 7 keys to podcast success, who and what is it for, and more!
Dr. John Cush RheumNow
3 years 5 months ago
COVID-19 Death is Dependent on Age and Type I IFN Autoantibodies
https://t.co/WrWujgHoA4 https://t.co/NTwUeXHYKr
Dr. John Cush RheumNow
3 years 5 months ago
506 ANCA-Assoc vasculitis pt study - 72% were MPO-ANCA+ & 68% w/ renal Dz, & Rx w/ RTX (59%) or CTX (33%) - 16% died, 10% ESRD & 13% relapsed. ANCA negativity had less relapse (HR 0.55; 0.38, 0.81) but not less ESRD or death @ 5 yrs https://t.co/iCrxH9UArl https://t.co/6s3TmQqxVQ
Dr. John Cush RheumNow
3 years 5 months ago
Japanese claims data study looked at hospitalizable infections (SIE) in RA pts based on age: young (16-64 y), old (65-74y), very old (>75y) and showed age related increase in SIE - 3.2, 5.0, and 10.1 SIE/100PY, respectively. (#s unaffected by biologic use)https://t.co/deaGy3g0Ai https://t.co/2A5mB8n4FK
Poster Hall